FDA declines expanded approval for Bristol-Myers' Opdivo drug
November 27, 2015 at 17:06 PM EST
Nov 27 (Reuters) - Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer.